Lipoprotein(a): the genetic heart risk one test can find.

Lipoprotein(a), pronounced "lipoprotein little a" and written Lp(a), is an LDL-like cholesterol particle carrying an extra protein that makes it unusually good at driving plaque, clots and aortic valve disease. Your level is 70–90% set by your genes and stays roughly flat your whole life. Around 1 in 5 people carry it at elevated levels, an estimated 1.4 billion worldwide, and almost none of them know, because Lp(a) is not part of a standard cholesterol panel. One blood test, once in a lifetime, settles the question.

Why this one behaves differently

Most cardiovascular risk factors are things you accumulated. Lp(a) is something you inherited. Roughly 20% of people sit above 125 nmol/L, the threshold that both the ACC/AHA and the European Atherosclerosis Society treat as risk-enhancing, and there is very little any of them can do to move the number itself. Diet, exercise and weight loss shift almost every other cardiovascular marker. They barely touch this one.

It is also causal rather than merely associated, which is a bar most cardiology headlines never clear. People who inherit Lp(a)-raising gene variants go on to have proportionally more heart attacks and more aortic stenosis. A dose-response relationship in genes handed out at random is the signature of cause rather than confounding, and it is why the field largely stopped arguing about Lp(a) a decade ago.

The frustrating part is that a completely clean cholesterol result from your GP tells you nothing about it. You have to ask for this test by name.

What the clinical evidence actually shows

Lp(a) has one of the deepest evidence bases of any marker sitting outside the standard panel, which is why it anchors the cardiovascular section of The HodieLabs Evidence-Based Clinical Library.

• Copenhagen General Population Study (Kamstrup et al. JAMA 2009): in tens of thousands of Danish adults, genetically elevated Lp(a) doubled to tripled myocardial infarction risk at the highest levels. Because the exposure was genetic, lifestyle confounding cannot explain it away.
• UK Biobank (Patel et al. ATVB 2021): across more than 400,000 participants, risk rose linearly with Lp(a), roughly 11% higher per 50 nmol/L. No safe plateau appeared anywhere in the range.
• NEJM genetic analysis (Thanassoulis et al. 2013): inherited variants in the LPA gene were the strongest genetic driver of aortic valve calcification found, establishing Lp(a) as the leading causal risk factor for calcific aortic stenosis, the most common valve disease of ageing.
• EAS 2022 consensus statement (Kronenberg et al. European Heart Journal): the definitive synthesis of 40 years of evidence. It concludes Lp(a) is a causal, independent cardiovascular risk factor, and recommends universal once-in-a-lifetime measurement with cascade screening of relatives when a level comes back high.

How to read your result

Every biomarker in the HodieLabs Evidence-Based Clinical Library is interpreted against published clinical authority standards, never against invented "optimal" ranges. For Lp(a) in nmol/L, the bands follow the EAS 2022 consensus and the ACC/AHA 2019 risk-enhancing thresholds:

• Below 75 nmol/L, optimal. Lp(a) is unlikely to be contributing much to your cardiovascular risk.
• 75–125 nmol/L, borderline. A grey zone. It may add modest risk, and it gets weighed against everything else on your panel.
• Above 125 nmol/L, elevated. The internationally recognised risk-enhancing threshold, and a reason to manage your modifiable risk factors considerably harder than you otherwise would.

"It's genetic, so why bother testing?"

The most common objection, and the answer is short. Knowing you carry high Lp(a) changes what you do about everything else.

Lp(a) amplifies the damage done by the risk factors you can control, so the same 20 point reduction in ApoB buys a person with elevated Lp(a) more than it buys someone without it. That person gains more from tighter blood pressure control, and more from a CT coronary calcium score that shows whether disease has already started. The EAS consensus frames a high reading exactly this way: not as a dead end, but as a reason to intensify prevention and to test first-degree relatives, each of whom has a substantial chance of carrying it too.

Targeted therapy is close, as well. Antisense and siRNA drugs cut Lp(a) by 80–95% in phase 2 trials published in the New England Journal of Medicine, and large phase 3 cardiovascular outcome trials are running now. If those read out positive, the people who already know their number will be first in the queue.

The Australian gap

Cardiovascular disease is involved in roughly one in four Australian deaths. Lp(a) testing is still rare here, because it sits outside the standard GP lipid panel and generally has to be requested specifically. So most of the one in five Australians carrying an elevated level have no idea. That is arguably the largest single blind spot in Australian preventative cardiology, and one inexpensive blood test closes it.

How testing works at HodieLabs

We measure Lp(a) in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, alongside ApoB, hs-CRP and the rest of the cardiovascular panel. A doctor interprets it against the thresholds above and in the context of your complete biomarker picture. If your level is high, the plan concentrates on the modifiable risks that matter most, with advanced screening such as CT calcium scoring where it is warranted.

Lp(a) is causal, common, invisible to standard testing, and stable for life. That combination makes it the textbook case for measuring once and knowing forever. If you have a family history of early heart disease, or you have simply never been tested, put it at the top of your list.

References

1. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946.
2. Kamstrup PR, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.
3. Patel AP, et al. Lp(a) concentrations and incident atherosclerotic cardiovascular disease: analysis in the UK Biobank. Arterioscler Thromb Vasc Biol. 2021;41:465–474.
4. Thanassoulis G, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512.
5. Tsimikas S, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244–255.
6. O'Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855–1864.

This article is general information, not medical advice. Speak with your GP about what testing and care is appropriate for you.